Beam Therapeutics, Inc.

The momentum for this stock is not very good. Beam Therapeutics, Inc. is not a good value stock. Beam Therapeutics, Inc. is not a good growth stock. Beam Therapeutics, Inc. is not very popular among insiders. Beam Therapeutics, Inc. is a mediocre stock to choose.

News

Beam Therapeutics (NASDAQ:BEAM) Price Target Raised to $69.00

Zolmax Beam Therapeutics (NASDAQ:BEAM - Free Report) had its target price increased by Stifel Nicolaus from $66.00 to $69.00 in a report published on Wednesday, Benzinga reports. Stifel Nicolaus currently...\n more…

Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings)

Benzinga In the latest quarter, 6 analysts provided ratings for Beam Therapeutics BEAM, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.\n more…

Beam Therapeutics price target raised to $69 from $66 at Stifel

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Simply Wall St There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...\n more…

Beam Therapeutics (NASDAQ:BEAM) Rating Reiterated by HC Wainwright

Zolmax HC Wainwright reaffirmed their buy rating on shares of Beam Therapeutics (NASDAQ:BEAM - Free Report) in a research report sent to investors on Thursday morning, Benzinga reports. HC Wainwright...\n more…

Beam Therapeutics Inc. (NASDAQ:BEAM) Receives $41.70 Consensus Price Target from Analysts

Zolmax Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) has earned an average recommendation of "Hold" from the twelve brokerages that are covering the firm, Marketbeat reports. Seven research...\n more…